Page 21 - Trials Network News Today

State health department to host Feb. 18 webinar on COVID-19 vaccine phases Posted: February 17, 2021 322 The Washington State Department of Health will host a live webinar Thursday, Feb. 18 to discuss the phasing and rollout of COVID-19 vaccines in state. The webinar, “Understanding WA’s COVID-19 Vaccine Phases,” will feature Umair A. Shah, MD, MPH, Secretary of Health; SheAnne Allen, COVID-19 vaccine director and Dr. Christopher Chen, medical director – Medicaid, Washington Hea...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

University System of Maryland (USM) effort includes video message, joint statement, and stepped-up campus advocacy activities. University of Maryland, Baltimore (UMB) President Bruce E. Jarrell, MD, FACS, has joined University System of Maryland (USM) Chancellor Jay A. Perman, MD, and presidents of the system’s other 11 universities in a special promotional effort to encourage COVID-19 vaccinations across Maryland. This multimedia campaign — designed to dovetail with state activities to pro...

Building trust in safe and effective COVID-19 vaccines Convincing millions to get vaccinated will take more than data, facts and figures January 21, 2021 • By Sabin Russell / Fred Hutch News Service Anthony Jackson, security coordinator for Fred Hutchinson Cancer Research Center, receives a dose of the new Pfizer-BioNTech COVID-19 vaccine on Jan. 19, 2021, at a new vaccine clinic set up on the Fred Hutch campus. Photo by Robert Hood /...

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months. The interim analysis assessed 468 case...

The ring has finally arrived! By Shobha Shukla - CNS JAN 29, 2021 You guessed it right. I am talking about the dapivirine vaginal ring (DPV-VR), which is one of the top advances happening in the field of microbicides. It is the first long acting prevention product whose Phase-3 randomised controlled studies have shown that using the dapivirine vaginal ring reduced the risk of HIV infection in women and long-term use was well-tolerated. The World Health Organization (WHO) has just recommended ...

The studies conducted jointly by the NIH -funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) showed that the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01, delivered intravenously once every eight weeks, was effective at preventing the acquisition of HIV strains that were sensitive to the antibody. This was assessed by a laboratory test that measures a virus’ susceptibility to neutralization by an antibody. Announcing the results during a press confe...

Antibody infusions prevent acquisition of some HIV strains An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy ...

Wednesday, 27 January 2021, 7:57 am Results of the Antibody Mediated Prevention (AMP) studies to be presented at the IAS HIV Research for Prevention (HIVR4P // Virtual) conference. Tuesday, 26 January, 2021 (Geneva, Switzerland) — IAS – the International AIDS Society – welcomes new results from two proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081- the AMP Studies) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent so...

Results will inform development of long-acting antibody-based HIV prevention tools. Scanning electromicrograph of an HIV-infected T cell. NIAID An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studie...